Greg Licholai, MD
Greg is President and Chief Medical Officer at Castle Creek Pharmaceuticals. He is a member of the Executive Leadership Team and is responsible for all research and development activities, technical operations, medical affairs and the company’s scientific, regulatory, medical and clinical strategies.
Previously he was founder and President of Elipdera Therapeutics, which is a Moderna Therapeutics venture portfolio company and focused on developing messenger RNA therapies for rare genetic and metabolic diseases. Dr. Licholai was a partner-level consultant at McKinsey & Company, where he ran a business line devoted to complex data analytics for pharmaceutical launches. He was Senior Vice President for Real World and Late Stage Research at Quintiles, Inc. He was Chief Operating Officer at Proteostasis, a biotechnology company focused on developing chaperones for rare disease. He was one of the original employees at Amicus Therapeutics, focused on pharmacological chaperones for rare diseases. He was also co-founder of Immunome, a biotechnology firm with a proprietary antibody platform for oncology. He was a venture capitalist at Domain Associates. He was director of Ventures and Business Development at Medtronic Neurological.
Dr. Licholai trained at the Brigham and Women’s, Children’s, and Massachusetts General Hospitals. He was a Howard Hughes Medical Institute Research Scholar at the National Institutes of Health. He performed research in molecular genetics at Yale University and examined variants in hereditary blood disorders. He worked in molecular oncology at Rockefeller University.
Dr. Licholai received a B.S. from Boston College and Pre-Medical studies at Columbia University, an M.D. from Yale Medical School and M.B.A from Harvard Business School. He is on the advisory board of the National Tay Sachs and Allied Disease Foundation and the Partnership for Palliative Care. He is on faculty at the Yale School of Management and teaches the capstone lectures in healthcare.